Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances

Zhang, Endong; Phan, Philana; Zhao, Zongmin

doi:10.1016/j.apsb.2022.08.020

Cited by 20 publications

(9 citation statements)

References 520 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of high immunogenicity, the use of senescent cell nanovesicles to stimulate an “antisenescent” immune response seems to be a promising and safe method to combat age-related senescent cell accumulation ( 63 , 86 , 87 ). However, there are currently no studies addressing this issue.…”

Section: Perspectivesmentioning

confidence: 99%

T-cell immunity against senescence: potential role and perspectives

Matveeva,

Vasilieva,

Minskaia

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The development of age-associated diseases is related to the accumulation of senescent cells in the body. These are old non-functional cells with impaired metabolism, which are unable to divide. Such cells are also resistant to programmed cell death and prone to spontaneous production of some inflammatory factors. The accumulation of senescent cells is related to the age-associated dysfunction of organs and tissues as well as chronic inflammation that enhances with age. In the young organism, senescent cells are removed with the innate immunity system. However, the efficiency of this process decreases with age. Nowadays, more and more evidences are accumulating to support the involvement of specific immunity and T-lymphocytes in the fight against senescent cells. It has great physiological importance since the efficient elimination of senescent cells requires a high diversity of antigen-recognizing receptors to cover the entire spectrum of senescent-associated antigens with high precision and specificity. Developing the approaches of T-cell immunity stimulation to generate or amplify a physiological immune response against senescent cells can provide new perspectives to extend active longevity. In this mini-review, the authors summarize the current understanding of the role of T-cell immunity in the fight against senescent cells and discuss the prospects of stimulating adaptive immunity for combating the accumulation of senescent cells that occurs with age.

show abstract

Section: Perspectivesmentioning

confidence: 99%

T-cell immunity against senescence: potential role and perspectives

Matveeva,

Vasilieva,

Minskaia

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…While EVs from CD3+, activated CD8+, or engineered T-cells, natural killer cells, and M1 macrophages are mostly considered immune-active nano-vesicles, EVs from regulatory T-cells, MSCs, and M2 macrophages, as well as erythrocytes, neutrophils, platelets or cancerous cells are reported to have immunosuppressive features. The key consideration is that they exert immunosuppressive or immune-active properties in a producer- and target-cell-dependent manner ( 67 ).…”

Section: Extracellular Vesicles a New Therapeutic Paradigm For Autoim...mentioning

confidence: 99%

Extracellular vesicles and their cells of origin: Open issues in autoimmune diseases

et al. 2023

View full text Add to dashboard Cite

The conventional therapeutic approaches to treat autoimmune diseases through suppressing the immune system, such as steroidal and non-steroidal anti-inflammatory drugs, are not adequately practical. Moreover, these regimens are associated with considerable complications. Designing tolerogenic therapeutic strategies based on stem cells, immune cells, and their extracellular vesicles (EVs) seems to open a promising path to managing autoimmune diseases’ vast burden. Mesenchymal stem/stromal cells (MSCs), dendritic cells, and regulatory T cells (Tregs) are the main cell types applied to restore a tolerogenic immune status; MSCs play a more beneficial role due to their amenable properties and extensive cross-talks with different immune cells. With existing concerns about the employment of cells, new cell-free therapeutic paradigms, such as EV-based therapies, are gaining attention in this field. Additionally, EVs’ unique properties have made them to be known as smart immunomodulators and are considered as a potential substitute for cell therapy. This review provides an overview of the advantages and disadvantages of cell-based and EV-based methods for treating autoimmune diseases. The study also presents an outlook on the future of EVs to be implemented in clinics for autoimmune patients.

show abstract

“…Stimulating immune cells to express endogenous antitumor substances and then extruding vesicles is also an essential strategy. Under suitable preparation, it is believed that activated or polarized immune vesicles retain the mRNA and miRNA contents of the original cells [ 79 ]. An intriguing endeavor in the field of research involved the fusion of mature DC vesicles with nanoparticles containing oxaliplatin.…”

Section: Applications and Approaches Using Cellular Vesiclesmentioning

confidence: 99%

Cellular-Membrane-Derived Vesicles for Cancer Immunotherapy

An,

Zeng,

Liu

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

The medical community is constantly searching for new and innovative ways to treat cancer, and cellular-membrane-derived artificial vesicles are emerging as a promising avenue for cancer immunotherapy. These vesicles, which are derived from mammal and bacteria cell membranes, offer a range of benefits, including compatibility with living organisms, minimal immune response, and prolonged circulation. By modifying their surface, manipulating their genes, combining them with other substances, stimulating them externally, and even enclosing drugs within them, cellular vesicles have the potential to be a powerful tool in fighting cancer. The ability to merge drugs with diverse compositions and functionalities in a localized area is particularly exciting, as it offers a way to combine different immunotherapy treatments for maximum impact. This review contains information on the various sources of these vesicles and discusses some recent developments in cancer immunotherapy using this promising technology. While there are still obstacles to overcome, the possibilities for cellular vesicles in cancer treatment are truly exciting.

show abstract

Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances

Cited by 20 publications

References 520 publications

T-cell immunity against senescence: potential role and perspectives

T-cell immunity against senescence: potential role and perspectives

Extracellular vesicles and their cells of origin: Open issues in autoimmune diseases

Cellular-Membrane-Derived Vesicles for Cancer Immunotherapy

Contact Info

Product

Resources

About